.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,374,747

« Back to Dashboard

Claims for Patent: 7,374,747

Title:Pharmaceutical foam
Abstract:The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
Inventor(s): Abram; Albert Zorko (Wantirna, AU), Hunt; Barry Thomas (Carnegie, AU)
Assignee: Stiefel Research Australia, Pty Ltd. (Rowville, AU)
Application Number:11/463,573
Patent Claims: 1. A method for treating a bacteria-mediated disease, said method comprising: applying a quick-breaking temperature sensitive foam composition to the skin of a subject in need thereof, said composition comprising: up to 15% w/w of clindamycin phosphate; from about 83% to about 97.9% w/w of a quick-breaking foaming agent, wherein said quick-breaking foaming agent comprises a C.sub.1-C.sub.6 alcohol, a C.sub.14-C22 alcohol, water, and a surfactant; from about 2% to about 7% w/w of an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons and a mixture thereof; and a base, to treat said bacteria-mediated disease.

2. The method of claim 1, wherein the amount of said C.sub.1-C.sub.6 alcohol in said quick-breaking foaming agent is from about 55% to about 65% w/w.

3. The method of claim 1, wherein the ratio of said C.sub.1-C.sub.6 alcohol to water is from about 1:7 to about 1:16.

4. The method of claim 1, wherein the ratio of said C.sub.1-C.sub.6 alcohol to water is less than about 1:7.

5. The method of claim 1, wherein the ratio of said C.sub.1-C.sub.6 alcohol to water is about 1.5:1 to about 1.8:1.

6. The method of claim 1, wherein the ratio of said C.sub.1-C.sub.6 alcohol to water is about 1.55:1 to about 1.75:1.

7. The method of claim 1, wherein the ratio of said C.sub.1-C.sub.6 alcohol to water is from about 1.5:1.

8. The method of claim 1, wherein said surfactant is present in an amount of from about 0.1% to about 10% w/w.

9. The method of claim 1, wherein said surfactant is selected from the group consisting of an ethoxylated non-ionic surfactant, an ethoxylated ionic surfactant, and a mixture thereof.

10. The method of claim 1, wherein said C.sub.1-C.sub.6 alcohol is ethanol.

11. The method of claim 1, wherein said C.sub.1-C.sub.6 alcohol is a mixture of ethanol and at least one other C.sub.1-C.sub.6 alcohol.

12. The method of claim 1, wherein the amount of said C.sub.14-C.sub.22 alcohol in said quick-breaking foaming agent is from about 1% to about 5% w/w.

13. The method of claim 12, wherein said C.sub.14-C.sub.22 alcohol is a C.sub.14-C.sub.20 alcohol.

14. The method of claim 13, wherein said C.sub.14-C.sub.20 alcohol is selected from the group consisting of cetyl alcohol, stearyl alcohol, and a mixture thereof.

15. The method of claim 14, wherein said C.sub.14-C.sub.20 alcohol is a mixture of cetyl alcohol and stearyl alcohol.

16. The method of claim 1, wherein said surfactant is a polysorbate.

17. The method of claim 1, further comprising an emollient.

18. The method of claim 1, wherein said base is a member selected from the group consisting of a bicarbonate, a carbonate, an alkali hydroxide, an alkaline earth metal hydroxide, and a transition metal hydroxide.

19. The method of claim 18, wherein said base wherein said base is potassium hydroxide.

20. The method of claim 1, wherein said bacteria-mediated disease is acne vulgaris.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc